AI-ECG: A New Market For A Century-Old Test

The 12-lead ECG hasn’t changed in a century. The algorithms reading it have. Three CEOs and one educator on whether doctors should trust the model

As Peptides Go Mainstream, CeliaRx Aims To Cut Through The Noise

As interest in peptide therapy continues to grow, CeliaRx is positioning itself as a trusted destination for personalized, physician-guided peptide care.

AI Startup Collate Raises $95 Million To Automate Life Sciences Paperwork

In this week’s edition of InnovationRx, we look at breakthroughs from ASCO, Harrison.ai’s U.S. expansion, Clear’s move into healthcare and more.

Knicks Karl-Anthony Towns, Pivotal In NBA Finals, Talks Pain, Recovery

New York Knicks big man Karl-Anthony Towns, who will play a big role against the San Antonio Spurs in the NBA Finals, talked how he manages his pain and recovery.

Caryn Seidman Becker Bought Clear Out Of Bankruptcy. Now She’s A Billionaire.

After conquering airport security checkpoints, Clear’s billionaire CEO Caryn Seidman Becker wants to use your biometrics to unlock doctors’ appointments, baseball games and the rest of your life.

The Uncomfortable Truth MAHA Is Exposing About US Healthcare

Whether American healthcare reorganizes around prevention will be a test of the quality of its leadership.

New Study Shows How mRNA Vaccines Could Transform Cancer Treatment

A doctor breaks down a new study on how mRNA vaccines in melanoma research could transform treatment and survival for cancer patients

Trump’s Most Favored Nation Drug Pricing Has Bold Aims, But Limited Impact

While the most favored nation initiatives have bold aims to lower the cost of drugs, the impact is limited, and in some instances unclear, a case of style over substance.

She Wasn’t Due For Her Colonoscopy. A Blood Test Found Cancer Anyway

A physician assistant with no symptoms and a clear colonoscopy was three years from her next screening. A blood test found Stage 3 colon cancer

Targeted Drug Shrinks Tumors In Hard-To-Treat Cancer

A targeted antibody‑drug conjugate shrinks tumors and slows progression in recurrent uterine cancer by ferrying potent chemotherapy directly into cancer cells.